Wiley Bros. Aintree Capital, LLC Caribou Biosciences, Inc. Transaction History
Wiley Bros. Aintree Capital, LLC
- $12.5 Billion
- Q2 2025
A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 336,565 shares of CRBU stock, worth $602,451. This represents 0.0% of its overall portfolio holdings.
Number of Shares
336,565Holding current value
$602,451% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRBU
# of Institutions
134Shares Held
43.6MCall Options Held
25KPut Options Held
53.2K-
Black Rock Inc. New York, NY6.95MShares$12.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.09MShares$7.32 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.07MShares$5.49 Million0.46% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY2.27MShares$4.07 Million0.02% of portfolio
-
Pictet Asset Management Sa Geneva 73, V81.81MShares$3.24 Million0.01% of portfolio
About Caribou Biosciences, Inc.
- Ticker CRBU
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,840,800
- Market Cap $109M
- Description
- Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...